Craft

Lyell

Stock Price

$2

2024-06-21

Market Capitalization

$522.6 M

2024-06-21

Revenue

$130 K

FY, 2023

Lyell Summary

Company Summary

Overview
Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors. Its technologies are designed to be applied in a target and modality agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL), and T cell receptor (TCR) therapies. The company develops Gen-R and Epi-R technology platforms to develop a multi-modality product.
Type
Public
Status
Active
Founded
2018
HQ
South San Francisco, CA, US | view all locations
Website
https://lyell.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Liz Homans

    Liz Homans, Chief Executive Officer

  • Richard Goold

    Richard Goold, Chief Information Officer

  • Stephen Hill

    Stephen Hill, Chief Technical Operations Officer

  • Lisa Ryan

LocationsView all

3 locations detected

  • South San Francisco, CA HQ

    United States

    201 Haskins Way

  • Bothell, WA

    United States

    2525 223rd St SE

  • Seattle, WA

    United States

    500 Fairview Ave N #560

Lyell Financials

Summary Financials

Revenue (Q1, 2024)
$3.0K
Net income (Q1, 2024)
($60.7M)
Cash (Q1, 2024)
$125.7M
EBIT (Q1, 2024)
($55.6M)
Enterprise value
$458.8M

Footer menu